Add Dr. Calendine as a preferred source on Google to see his answers first in your search and AI results.
More of my patients take a GLP-1 medication every year, mostly semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound). Now a large study presented at the 2026 meeting of the American Academy of Orthopaedic Surgeons has put a number on GLP-1 osteoporosis risk, and the headline sounds alarming.
The real number is smaller than the headline, and it applies to a specific group. I’m an orthopedic surgeon who performs more than 700 hip and knee replacements a year, and bone is what my implants hold on to. This isn’t a statement for or against these drugs. Just the facts, and what I’d do about them.
What Did the 2026 AAOS Study Find About GLP-1 Osteoporosis Risk?
Adults with type 2 diabetes and obesity who took a GLP-1 were diagnosed with osteoporosis more often over five years than closely matched adults who didn’t. Osteoporosis means bones that have lost enough mineral and structure to break more easily.[1]
The team, led by Muaaz Wajahath at Michigan State University, used a national medical records database. They matched 73,483 GLP-1 users with 73,483 non-users for age, sex, body mass index (BMI), blood sugar control, smoking, kidney disease and existing osteoporosis, among other factors. The drugs were semaglutide, liraglutide, dulaglutide and exenatide.[1] The AAOS press release covers it alongside a second GLP-1 study.
| New diagnosis | GLP-1 users | Non-users | Relative risk | Extra cases per 1,000 |
|---|---|---|---|---|
| Osteoporosis | 4.1% | 3.2% | 1.29 (29% higher) | About 9 |
| Gout | 7.4% | 6.6% | 1.12 (12% higher) | About 8 |
| Osteomalacia | 0.2% | 0.1% | 2.55 | About 1 |
What the GLP-1 osteoporosis risk numbers mean in plain terms
A 29% increase sounds large. But out of every 1,000 people in each group, about 32 non-users and 41 GLP-1 users were diagnosed with osteoporosis over five years.
This was an observational study. It shows that GLP-1 use and osteoporosis went together, not that the drug caused the bone loss.
Does This Apply If You Take a GLP-1 Only for Weight Loss?
Not directly. Every patient in the AAOS study had both type 2 diabetes and obesity, so the 29% figure belongs to that group.[1] I’ve seen it applied online to people who take a GLP-1 only to lose weight. That goes beyond what the study measured.
For people without diabetes, the bone question hasn’t been answered either way.
Why Would a GLP-1 Affect Your Bones?
Any rapid weight loss can affect your bones, and that is the most likely reason here. Bone responds to load. Carry less weight, and the skeleton gets the signal to break down more bone than it builds.
A 2025 review found that losing roughly 7% to 10% of body weight, by dieting or weight-loss surgery, causes this kind of bone loss. Early GLP-1 data show the same pattern.[3]
In a 2024 randomized trial, 64 adults at higher fracture risk, mostly women past menopause, took weekly semaglutide or a placebo for a year. The semaglutide group lost about 6.8 kg (15 pounds) more and ended with about 2.6% less hip bone density and 2% less spine density than the placebo group. The authors thought the weight loss could explain it.[2]
In another 2024 trial, adults on liraglutide alone lost more hip and spine bone density than adults who exercised alone, with similar weight loss.[4] Whether the drugs act on bone directly is unknown. Muscle loss matters too, and I cover it in GLP-1 before surgery.
Does GLP-1 Use Mean More Broken Bones?
Not clearly. The AAOS study counted osteoporosis diagnoses, not fractures, and the fracture data point in different directions.
The strongest warning is on the FDA label for Wegovy. In a large heart outcomes trial in adults, women on Wegovy had more hip and pelvis fractures than women on placebo: 1% (24 of 2,448) vs. 0.2% (5 of 2,424). Adults 75 and older showed the same pattern, 2.4% vs. 0.6%, according to the Wegovy prescribing information.
A 2026 analysis of 60 studies and more than 1.25 million people found no significant effect on bone density or fractures. It did find lean mass loss, and the authors rated the certainty of the evidence low.[5]
Not every GLP-1 may act the same way. In a 2025 records study of about 66,000 matched patients per group, people starting tirzepatide had a 44% higher rate of osteoporosis or fragility fracture over 14 months than people starting another GLP-1.[6] It’s one study with short follow-up. The evidence is early and mixed, but it’s not too early for a warning.
What About Gout and Osteomalacia?
Both rose and both stayed uncommon. Gout is a painful arthritis caused by uric acid crystals in a joint. It went from 6.6% to 7.4%.[1] I wrote about how gout can mimic infection in gout after knee replacement.
Osteomalacia means soft bones that don’t mineralize properly. Its relative risk was 2.55, but it went from only 0.1% to 0.2%.[1]
Why Does Bone Quality Matter to a Joint Replacement Surgeon?
A hip or knee replacement is only as secure as the bone it sits in. The implant has to grip or bond to living bone, and that bone has to carry you for decades.
In the first months after surgery, while you rebuild strength and balance, a fall can break weaker bone around the implant. I explain how that heals in fracture after hip replacement. No study has shown that GLP-1 drugs cause implant problems. But if you take one and may need a joint replaced someday, check your bone health before that day comes.
Who Has the Highest GLP-1 Osteoporosis Risk?
We don’t know yet what happens after 65 to someone who has taken a GLP-1 for ten years. Our fear as surgeons is more broken hips. Muscle and bone come off together, and after 65, bone doesn’t come back easily. The people I’d watch most closely:
- Women past menopause (more hip and pelvis fractures on the Wegovy label)
- Adults 75 and older (the same pattern)
- Anyone who already has low bone density or a past fracture from a minor fall
- People losing a large share of their body weight, especially without strength training
- Long-term users, since the AAOS signal appeared over five years
How Can You Protect Your Bones on a GLP-1?
You can lower your GLP-1 osteoporosis risk with steps that also protect your muscles and joints. None of them requires stopping the medication, and you should never stop or change a GLP-1 without talking to the doctor who prescribed it.

- Ask about a bone density scan. Has your doctor ever mentioned your bones? A DEXA scan is a quick, low-dose X-ray of bone density. In a higher-risk group, a baseline scan gives you and your doctor a starting point.
- Lift something. In the 2024 liraglutide trial, people who combined the drug with exercise kept their hip and spine bone density compared with placebo, while losing the most weight of any group.[4]
- Eat enough protein, calcium and vitamin D. With a smaller appetite, it’s easy to fall short. My guide to calcium and vitamin D supplements covers who benefits.
- Prevent falls. A fracture usually needs both weak bone and a fall. Here are my steps to prevent hip fractures.
For the broader plan, see how to prevent osteoporosis.
In the news
The Washington Times asked me about GLP-1 hype for a November 2026 report. I told the reporter that what worries me is the drug taken alone: “no protein target, no lifting, no plan for the day it stops.” I also raised compounded versions bought online, where no one is checking muscle or bone. Read the full Washington Times article.
Is There Any Good News for Surgery Patients?
Yes. A second AAOS study of 10 common orthopedic surgeries found that GLP-1 users had fewer emergency visits after surgery and fewer wound infections after hip and knee replacement. More on what these drugs can do for arthritis in can GLP-1s help you avoid joint replacement.
These drugs help many people, and the GLP-1 osteoporosis risk is real but modest. Protect yourself, especially during periods of weight loss.
GLP-1 and Bone Health Care in Franklin and Nashville
I see patients from Franklin, Nashville, Brentwood, Columbia, and across Middle Tennessee at the Bone and Joint Institute of Tennessee. If you take a GLP-1 and have hip or knee pain or are planning a joint replacement, we can review your bone health at that visit.
You can schedule an appointment online or call (615) 791-2630. The clinic is at 3000 Edward Curd Lane, Franklin, TN 37067.
This article is for educational purposes only and is not a substitute for professional medical advice. Do not start, stop, or change a GLP-1 medication or any bone treatment without talking to your prescribing doctor. Individual results may vary. In a medical emergency, call 911.
References
- Wajahath M, Lawand JJ, Hill BW, Khan A, Abboud JA, Horneff JG. GLP1 receptor agonist use is associated with increased risk of osteoporosis, gout, and osteomalacia in adults with type 2 diabetes and obesity. Paper presented at: American Academy of Orthopaedic Surgeons 2026 Annual Meeting; March 2-6, 2026; New Orleans, LA. Abstract
- Hansen MS, Wölfel EM, Jeromdesella S, et al. Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial. eClinicalMedicine. 2024;72:102624. doi:10.1016/j.eclinm.2024.102624
- Karam L, Mabilleau G, Paccou J. Effects of glucagon-like peptide-1 receptor agonists on bone health in people living with obesity. Osteoporos Int. 2025;36(11):2115-2126. doi:10.1007/s00198-025-07664-1
- Jensen SBK, Sørensen V, Sandsdal RM, et al. Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment: a secondary analysis of a randomized clinical trial. JAMA Netw Open. 2024;7(6):e2416775. doi:10.1001/jamanetworkopen.2024.16775
- Beaudart C, Malréchauffé Y, van Heden S, et al. GLP-1 receptor agonists and musculoskeletal outcomes: a systematic literature review and meta-analysis. Drugs. 2026;86(10):1661-1691. doi:10.1007/s40265-026-02365-3
- Hsu YH, Liang YC, Chan KC, et al. Association of tirzepatide use with risk of osteoporosis compared with other GLP-1 receptor agonists: a retrospective cohort study using the TriNetX database. Diabetes Res Clin Pract. 2025;230:112995. doi:10.1016/j.diabres.2025.112995

